View clinical trials related to Hypercholesterolemia.
Filter by:The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.
In this study, within the secondary prevention group patients ( diabetes mellitus, coronary artery disease, peripheral artery disease, who have had events atherosclerotic cerebrovascular ) , statin use requirement , patients compliance and reaching target LDL-cholesterol levels (according to European guidelines ) will be evaluated.
A large body of evidence confirm the cholesterol lowering effect of phytosterols and red yeast rice. Because their mechanisms of action mime the ones of chemical statins and cholesterol absorption inhibitors, it is plausible that their association will provide a more relevant (and safe) LDL cholesterolemia reduction.
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial hypercholesterolemia) and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of ALN-PCSSC injection(s).
The primary purpose of this placebo-controlled study is to evaluate the low‐density lipoprotein cholesterol (LDL‐C) efficacy and dose‐response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination with atorvastatin 10, 40, and 80 mg/day to hypercholesterolemic patients. Secondary purposes include evaluating the effects of high‐sensitivity C-reactive protein (hsCRP), high‐density lipoprotein cholesterol (HDL‐C), triglycerides (TG) and apolipoprotein B (ApoB), and safety and efficacy of gemcabene monotherapy and gemcabene/atorvastatin combination.
The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of atorvastatin 80 mg
The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of simvastatin 80 mg.
The purpose of this study is to evaluate the multiple‐dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
The purpose of this study is to evaluate the effect of gemcabene on HDL‐C, LDL‐C, TG, and other lipid levels in patients with low HDL‐C